- Home
- KEY vs WST Comparison
KEY vs WST Comparison
Compare KEY & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEY | WST |
|---|---|---|
| Founded | 1825 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 20.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KEY | WST |
|---|---|---|
| Price | $21.53 | $281.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $21.18 | ★ $345.75 |
| AVG Volume (30 Days) | ★ 15.8M | 674.2K |
| Earning Date | 01-20-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.84% | 0.32% |
| EPS Growth | ★ 34785.88 | 0.17 |
| EPS | 0.86 | ★ 6.75 |
| Revenue | ★ $5,934,000,000.00 | $3,017,900,000.00 |
| Revenue This Year | $77.38 | $7.01 |
| Revenue Next Year | $6.69 | $6.20 |
| P/E Ratio | ★ $24.71 | $41.33 |
| Revenue Growth | ★ 22.30 | 4.92 |
| 52 Week Low | $12.73 | $187.43 |
| 52 Week High | $21.74 | $348.90 |
Technical Indicators
Market Signals| Indicator | KEY | WST |
|---|---|---|
| Relative Strength Index (RSI) | 72.42 | 56.97 |
| Support Level | $20.49 | $269.55 |
| Resistance Level | $21.74 | $277.75 |
| Average True Range (ATR) | 0.32 | 6.91 |
| MACD | -0.04 | 1.03 |
| Stochastic Oscillator | 84.13 | 60.85 |
Price Performance
Historical ComparisonAbout KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.